Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in 
resectable non-small cell lung cancer: First clinical experience

Eichhorn, Florian; Klotz V, Laura; Kriegsmann, Mark; Bischoff, Helge; Schneider, Marc A.; Muley, Thomas; Kriegsmann, Katharina; Haberkorn, Uwe; Heussel, Claus Peter; Savai, Rajkumar; Zoernig, Inka; Jaeger, Dirk; Thomas, Michael; Hoffmann, Hans; Winter, Hauke; Eichhorn, Martin E.

doi:10.1016/j.lungcan.2021.01.018

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience

MPS-Authors

/persons/resource/persons224330

Savai, Rajkumar
Lung Development and Remodeling, Max Planck Institute for Heart and Lung Research, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Eichhorn, F., Klotz V, L., Kriegsmann, M., Bischoff, H., Schneider, M. A., Muley, T., et al. (2021). Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience. LUNG CANCER, 153, 150-157. doi:10.1016/j.lungcan.2021.01.018.

Cite as: https://hdl.handle.net/21.11116/0000-0008-2D63-7

Abstract

There is no abstract available